Real world evidence (RWE) study of ZYTIGA (Abiraterone Acetate) plus prednisone for the treatment of asymptomatic and mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Trial Profile

Real world evidence (RWE) study of ZYTIGA (Abiraterone Acetate) plus prednisone for the treatment of asymptomatic and mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2017 New trial record
    • 17 Feb 2017 According to a Janssen media release, results from this study were presented at American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
    • 17 Feb 2017 Results published in the Janssen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top